Capricor’s Duchenne therapy has new life after FDA grants 3-month extension

RegulatoryderamiocelPositive

AI Analysis

Summary

The FDA granted Capricor Therapeutics a three-month extension to review additional data for deramiocel, its Duchenne muscular dystrophy therapy, with a new target action date of November 22, 2026.

Outcome Details

FDA granted 3-month extension for additional data review and refined indication consideration

Importance:6/10

Sentiment:

0.60

FDAextensionDuchenne muscular dystrophyregulatoryderamiocel

Related Companies

$CBDY

Read the original article

Published by BioSpace on August 24, 2026 3:28 PM

Read Original